Recurrent Peptic Ulcer due to Carcinoid Tumour of Jejunum

Bhattacharyya, Parimal
August 2011
Indian Journal of Surgery;Aug2011, Vol. 73 Issue 4, p298
Academic Journal
Carcinoid Tumours are classified as Neuro-endocrine tumours. Commonly known ulcerogenic neuro-endocrine tumour is Gastrinoma of the Pancreas and Duodenum.It secretes hormone Gastrin which causes hyperplasia of the gastric parietal cells with excessive secretion of hydrochloric acid resulting in multiple ulcerations in the stomach, duodenum and upper jejunum. Carcinoid tumours is not known to cause peptic ulceration.


Related Articles

  • High- Versus Low-Dose Proton Pump Inhibitors After Endoscopic Hemostasis in Patients With Peptic Ulcer Bleeding: A Multicentre, Randomized Study. Andriulli, Angelo; Loperfido, Silvano; Focareta, Rosaria; Leo, Pietro; Fornari, Fabio; Garripoli, Antonietta; Tonti, Paolo; Peyre, Sergio; Spadaccini, Antonio; Marmo, Riccardo; Merla, Antonio; Caroli, Alessandro; Forte, Gian Battista; Belmonte, Angelo; Aragona, Giovanni; Imperiali, Gianni; Forte, Fabrizio; Monica, Fabio; Caruso, Nazario; Perri, Francesco // American Journal of Gastroenterology;Dec2008, Vol. 103 Issue 12, p3011 

    BACKGROUND: The most effective schedule of proton pump inhibitor (PPI) administration following endoscopic hemostasis of bleeding ulcers remains uncertain. METHODS: Patients with actively bleeding ulcers and those with nonbleeding visible vessel or adherent clot were treated with epinephrine...

  • H. PYLORI ERADICATION OPTIONS FOR PEPTIC ULCER DISEASE.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, p126 

    A table is presented which lists proton-pump inhibitor drugs for treating peptic ulcers including Aciphex, Prevacid and Helidac.

  • PPI treatment beneficial to patients with ulcer bleeding, according to meta-analysis.  // Formulary;Jun2007, Vol. 42 Issue 6, p391 

    The article focuses on the study that examines the benefits of proton-pump inhibitors (PPIs) for patients with ulcer bleeding. According to the study, the use of PPIs for ulcer bleeding effectively reduces the risk of bleeding and the need for surgical intervention and repeated endoscopic...

  • H. PYLORI ERADICATION OPTIONS FOR PEPTIC ULCER DISEASE.  // Monthly Prescribing Reference;Nov2012, Vol. 28 Issue 11, p120 

    A table is presented which lists several treatment options for peptic ulcer disease which includes proton pump inhibitor-based treatments, combination therapy and H 2 receptor antagonist-based treatments.

  • Case of the Month. West, Lara M. // JAAPA: Journal of the American Academy of Physician Assistants (;Nov2011, Vol. 24 Issue 11, p83 

    The article presents a case study of a 74-year-old who was taken to the emergency department (ED) with complaints of right upper quadrant (RUQ) abdominal pain and right-sided shoulder pain. Upon examination, the abdomen was soft, nondistended with mild pain in the RUQ, positive Murphy sign and...

  • H. PYLORI ERADICATION OPTIONS FOR PEPTIC ULCER DISEASE.  // Monthly Prescribing Reference;Oct2013, Vol. 29 Issue 10, p134 

    A table is presented which lists several therapeutic drugs for the treatment of peptic ulcer disease which include the Helidac as combination therapy, the nizatidine as antagonist-based treatment and the Nexium as proton pump inhibitor-based treatment.

  • The Infusion Illusion. Targownik, Laura E.; Thomson, Peter A. // American Journal of Gastroenterology;Dec2008, Vol. 103 Issue 12, p3019 

    Currently, the standard of care for high-risk peptic ulcer bleeding involves the use of a continuous intravenous proton pump inhibitor (PPI) infusion over 72 h. However, the article by Andruilli et al. details the results of a randomized controlled trial indicating that a less intensive regimen...

  • H2RBs vs PPIs part 2: histamine-2 receptor blockers as a first-line agent for peptic ulcer disease prophylaxis. Regidor, Ronnell // Gastrointestinal Nursing;Jul/Aug2013, Vol. 11 Issue 6, p25 

    In the first part of this two-part series, the author reviewed several studies assessing the clinical scenarios in which histamine-2 receptor blockers (H2RBs) and proton pump inhibitors (PPIs) should be used. Although H2RBs and PPIs have been used extensively in the treatment of peptic ulcer...

  • AVOIDING REFLUX WHEN STOPPING PPIS. SUMNER, PAULA J.; Bryan, Rebecca H. // Clinical Advisor;Sep2011, Vol. 14 Issue 9, p62 

    The article provides an answer to a question of whether proton pump inhibitors (PPIs) can be reduced without causing reflux in geriatric patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics